sickle cell treatment (Albert Einstein/Cengent)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Namesickle cell treatment (Albert Einstein/Cengent)
Drug Alias Namesickle cell treatment (Albert Einstein/SBI)sickle cell treatment (Albert Einstein/Structural Bioinformatics)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHemoglobins modulators
TargetsHemoglobins
Therapy Area/IndicationsAnemia, Sickle Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAlbert Einstein College Of Medicine Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCengent Therapeutics IncAlbert Einstein College Of Medicine Inc
Active IndicationsN/A
Inactive IndicationsAnemia, Sickle Cell

Other Information

ATC CodeN/A
Related LinksN/A